Corrine Savill - 18 Jul 2022 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Acting Chief Business Officer
Signature
/s/ Jeffrey Trigilio, Attorney-in-Fact
Issuer symbol
CGEM
Transactions as of
18 Jul 2022
Transactions value $
-$303,593
Form type
4
Filing time
21 Jul 2022, 16:30:37 UTC
Previous filing
12 Jul 2022
Next filing
21 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Sale -$75,932 -5,042 -2.97% $15.06 164,573 18 Jul 2022 Direct F1, F2
transaction CGEM Common Stock Sale -$227,660 -14,958 -9.09% $15.22 149,615 19 Jul 2022 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 9, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.16. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.40. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.